Remove 2003 Remove Intellectual Property Law Remove Patent
article thumbnail

Intersection of Intellectual Property Law and Competition Law with respect to Cross Licensing Agreements

IIPRD

However, the population and their necessities as well as demands have increased manifold which has culminated into a need to regularize invention by bilateral or multilateral collaborations in order to drive innovation and help the masses in increasing their access to latest technological developments along with preventing monopolization of patents.

article thumbnail

Intellectual Property Law and Competition Law: Conflicting or Complementing

IIPRD

Introduction If we take a broader look at the Intellectual Property Laws, the primary objective of the legislation in framing these laws is to provide exclusive rights to the IP right holder as against the entire world. In contrast, the CCI has the authority to decide upon all the happenings in the market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Copyrightability of a Programming Language

Patently-O

New briefs in support of the accused infringer WPL: Electronic Frontier Foundation (EFF) : The law treats copyrightability of software differently than other literary works (as it should). Patents should be the go-to in this area. I’ll note that EFF has also repeatedly argued against patentability of software.

Copyright 109
article thumbnail

Understanding Freedom to Operate (FTO) Concerning IP & Patents

Kashishipr

Three pharmaceutical companies, including Enzon Pharmaceuticals, Micromet AG, and Cambridge Antibody Technology (now acquired by AstraZeneca), in September 2003 announced signing a non-exclusive cross-license agreement. Without any doubt, stepping into patent litigation can be uncertain, full of risks, and expensive.

IP 105
article thumbnail

Arbutus Biopharma Corporation, FKA Protiva Biotherapeutics, Inc., v. Modernatx, Inc., FKA Moderna Therapeutics, Inc. No. 2020-1183 (Fed. Cir. April 11, 2023)

Intellectual Property Law Blog

Background The ’127 patent is directed to an invention that provides stable nucleic acid-lipid particles (“SNALP”) that have non-lamellar structure and “comprise a nucleic acid … methods of making SNALP, and methods of delivering and/or administering the SNALP.” ’127 127 patent, Abstract. 127 patent, col. 127 patent, col.

Art 130
article thumbnail

PTAB’s Authority to Issue a Final Written Decision After a Statutory Deadline

Intellectual Property Law Blog

21, 2023) , the case addresses the Patent Trial and Appeal Board’s (“PTAB’s”) authority to issue a Final Written Decision in a post grant review (“PGR”) after the prescribed statutory deadline. 9,693,961 (“the ‘961 patent”). In March 2018, Collegium petitioned the PTAB for PGR of claims 1-17 of the ‘961 patent.

article thumbnail

The Changing Jurisdictional Journey of Intellectual Property Rights and Competition Law

IIPRD

Background IPR laws give exclusive and protective rights to manufacture and sell a product, service, or technology that is created from an intellectual creation. Articles 40 and 30 of the TRIPS Agreement address limited exceptions to patent rights and anti-competitive activities in contractual licensing, respectively.